INTRODUCTION {#s1}
============

Based on the GLOBOCAN2012 investigations, approximately 14.1 million new cancer cases and 8.2 million deaths were reported worldwide \[[@R1]\]. The overall incidence of brain tumor is estimated at 3.5 case per 100,000 persons, and glioma and meningioma are the most common types of primary brain tumors, accounting for approximately 50% and 20%, respectively \[[@R2], [@R3]\]. Primary brain tumors mostly occur in familial aggregation, indicating important role of genetic variants in the pathogenesis of brain tumor \[[@R4]\].

Folate metabolism plays an important role in carcinogenesis, due to its involvement in DNA synthesis, methylation and repair. Folate metabolism regulates nucleotide synthesis and DNA methylation via a complex pathway involving at least 30 different enzymes \[[@R5]\]. Therefore, individual genetic variation in these enzymes could change the general balance between DNA synthesis, methylation, and repair. The genes encoding enzymes involved in folate metabolism display several single nucleotide polymorphisms, such as methylenetetrahydrofolate reductase (MTHFR A1298C) and methionine synthase reductase (MTRR A66G). Genetic polymorphisms of folate metabolism pathways have been shown to be associated with diverse tumor types, including pancreatic cancer \[[@R6]\], cervical intraepithelial neoplasia \[[@R7]\], breast cancer \[[@R8]\] and acute leukemia \[[@R9]--[@R11]\].

Semmler et al. reported the first case-control study showing that A1298C genetic variant was not significantly associated with brain tumor susceptibility \[[@R12]\]. Up to now, the two most common Folate Metabolism genetic variants A1298C (rs1801131) and A66G (rs1801394) have been studied for their associations with brain tumor susceptibility, but the results from published articles are controversial and inconclusive \[[@R12]--[@R16]\]. We hypothesized that the inconsistent results may have been caused by either the relatively small sample sizes of single studies or the genetic heterogeneity of folate metabolism genetic variants in different populations. Therefore, we performed this meta-analysis including all studies available to evaluate the relationship between folate metabolism genetic polymorphisms and the susceptibility to meningioma and glioma in adults. To our knowledge, this is the first comprehensive and systematic meta-analysis to investigate the relationship between genetic polymorphisms of folate metabolism and meningioma and glioma susceptibility in adults.

RESULTS {#s2}
=======

Characteristics of eligible publications {#s2_1}
----------------------------------------

After screening the abstracts, titles, or contents through EMBASE, PubMed and the Cochrane Library, we identified 72 potentially relevant studies and selected five published studies \[[@R12]--[@R16]\]. The flow diagram describing the selection of the studies is shown in Figure [1](#F1){ref-type="fig"}. All selected studies were case-control study, their population size ranged from 154 to 1,200, and were published from 2006 to 2013. All SNPs tested indicated that genotype frequencies in the controls are consistent with the HWE (P \> 0.001). The characteristics of the selected studies are summarized in Table [1](#T1){ref-type="table"}.

![Flow chart of study selection in this meta-analysis](oncotarget-08-57265-g001){#F1}

###### Main characteristics of studies included in the meta-analysis

           Author    Year   Country        Ethnicity   Cancer type   Control source   Genotyping methods   Case   Control   HWE
  -------- --------- ------ -------------- ----------- ------------- ---------------- -------------------- ------ --------- -------
  A1298C                                                                                                                    
           Semmler   2008   German         Caucasian   Meningioma    PB               PCR-RFLP             100    100       0.842
           Zhang     2013   China          Asian       Meningioma    PB               PCR-RFLP             600    600       0.199
           Bethke    2008   UK-North       Caucasian   Meningioma    PB               lllumina             173    175       0.219
           Bethke    2008   UK-Southeast   Caucasian   Meningioma    PB               lllumina             121    123       0.423
           Bethke    2008   Sweden         Caucasian   Meningioma    PB               lllumina             149    149       0.759
           Bethke    2008   Denmark        Caucasian   Meningioma    PB               lllumina             110    113       0.104
           Bethke    2008   Finland        Caucasian   Meningioma    PB               lllumina             77     77        0.783
           Li        2013   China          Asian       Meningioma    PB               PCR-RFLP             317    320       0.063
           Bethke    2008   UK-North       Caucasian   Glioma        PB               lllumina             369    369       0.029
           Bethke    2008   UK-Southeast   Caucasian   Glioma        PB               lllumina             211    214       0.564
           Bethke    2008   Sweden         Caucasian   Glioma        PB               lllumina             197    196       0.495
           Bethke    2008   Denmark        Caucasian   Glioma        PB               lllumina             99     100       0.798
           Bethke    2008   Finland        Caucasian   Glioma        PB               lllumina             128    131       0.746
           Liu       2013   China          Asian       Glioma        HB               PCR                  273    326       0.008
  A66G                                                                                                                      
           Zhang     2013   China          Asian       Meningioma    PB               PCR-RFLP             600    600       0.765
           Bethke    2008   UK-North       Caucasian   Meningioma    PB               lllumina             174    175       0.733
           Bethke    2008   UK-Southeast   Caucasian   Meningioma    PB               lllumina             121    123       0.756
           Bethke    2008   Sweden         Caucasian   Meningioma    PB               lllumina             149    149       0.641
           Bethke    2008   Denmark        Caucasian   Meningioma    PB               lllumina             110    113       0.9
           Bethke    2008   Finland        Caucasian   Meningioma    PB               lllumina             77     77        0.361
           Bethke    2008   UK-North       Caucasian   Glioma        PB               lllumina             128    131       0.212
           Bethke    2008   UK-Southeast   Caucasian   Glioma        PB               lllumina             370    369       0.966
           Bethke    2008   Sweden         Caucasian   Glioma        PB               lllumina             211    214       0.477
           Bethke    2008   Denmark        Caucasian   Glioma        PB               lllumina             197    197       0.872
           Bethke    2008   Finland        Caucasian   Glioma        PB               lllumina             99     100       0.017

PB, population-based; HB, hospital-based; HWE, Hardy-Weinberg equilibrium.

Association between A66G polymorphism and the susceptibility of meningioma and glioma in adults {#s2_2}
-----------------------------------------------------------------------------------------------

Meta-analysis of A66G polymorphism in 2,236 cases and 2,248 controls showed a significant association between A66G and the risk of meningioma and glioma (G vs. A: OR=1.11, 95%CI=1.02-1.20; GG vs. AA: OR=1.22, 95%CI=1.03-1.45; GG vs. AA+AG: OR=1.17, 95%CI=1.00-1.36) (Figure [2](#F2){ref-type="fig"}). Stratification analysis by tumor type showed a significant association of A66G polymorphism with meningioma (G vs. A: OR=1.18, 95%CI=1.05-1.32; GG vs. AA: OR=1.41, 95%CI=1.12-1.77; GG vs. AA+AG: OR=1.32, 95%CI=1.07-1.63; GG+AG vs. AA: OR=1.19, 95%CI=1.01-1.40), but not with glioma. We also implemented stratified analysis by ethnicity, and found a significant association in Asian population (GG vs. AA: OR=1.41, 95%CI=1.02-1.96) (Table [2](#T2){ref-type="table"}).

![Forest plot on the association between A66G (rs1801394) and meningioma and glioma susceptibility in adults in the allele model\
**(A)** Overall analysis. **(B)** Subgroup analysis by cancer type.](oncotarget-08-57265-g002){#F2}

###### Meta-analysis of the association between A66G polymorphism and brain tumor susceptibility in adults

  Comparison     Subgroup     Studies   Heterogeneity test   Association test   Model                 Publication bias               
  -------------- ------------ --------- -------------------- ------------------ --------------------- ------------------ --- ------- -------
  G vs. A        Overall      11        0.184                27.4               **1.11(1.02-1.20)**   **0.02**           F   0.35    0.262
                 Meningioma   5         0.447                0                  **1.18(1.05-1.32)**   **0.004**          F           
                 Glioma       6         0.185                35.5               1.02(0.90-1.16)       0.748              F           
                 Caucasian    10        0.155                31.7               1.08(0.98-1.19)       0.109              F           
                 Asian        1         NA                   NA                 1.17(0.99-1.37)       0.062              F           
  AG vs. AA      Overall      11        0.806                0                  1.08(0.95-1.23)       0.235              F   0.755   0.52
                 Meningioma   5         0.447                0                  1.12(0.94-1.33)       0.226              F           
                 Glioma       6         0.891                0                  1.04(0.86-1.27)       0.669              F           
                 Caucasian    10        0.752                0                  1.10(0.95-1.29)       0.205              F           
                 Asian        1         NA                   NA                 1.03(0.80-1.32)       0.836              F           
  GG vs. AA      Overall      11        0.089                39                 **1.22(1.03-1.45)**   **0.023**          F   0.213   0.178
                 Meningioma   5         0.527                0                  **1.41(1.12-1.77)**   **0.004**          R           
                 Glioma       6         0.054                57.1               0.95(0.62-1.44)       0.801              R           
                 Caucasian    10        0.079                41.7               1.16(0.95-1.41)       0.156              F           
                 Asian        1         NA                   NA                 **1.41(1.02-1.96)**   **0.04**           F           
  GG+AG vs. AA   Overall      11        0.648                0                  1.12(0.99-1.27)       0.074              F   0.876   0.813
                 Meningioma   5         0.394                3.5                **1.19(1.01-1.40)**   **0.04**           F           
                 Glioma       6         0.836                0                  1.04(0.86-1.25)       0.705              F           
                 Caucasian    10        0.554                0                  1.12(0.97-1.29)       0.132              F           
                 Asian        1         NA                   NA                 1.12(0.89-1.42)       0.336              F           
  GG vs. AA+AG   Overall      11        0.083                39.8               **1.17(1.00-1.36)**   **0.043**          F   0.161   0.08
                 Meningioma   5         0.707                4.6                **1.32(1.07-1.63)**   **0.009**          R           
                 Glioma       6         0.024                64.5               0.93(0.61-1.40)       0.711              R           
                 Caucasian    10        0.09                 40.2               1.10(0.92-1.31)       0.294              F           
                 Asian        1         NA                   NA                 **1.39(1.03-1.87)**   **0.029**          F           

OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not available; PB, population-based; HB, hospital-based

Association between A1298C polymorphism and the susceptibility of meningioma and glioma in adults {#s2_3}
-------------------------------------------------------------------------------------------------

Summary of the association of A1298C polymorphic variant with the risk of meningioma and glioma in adults including 2,997 cases and 3,403 controls is shown in Table [3](#T3){ref-type="table"}. Pooled risk evaluation showed a significant association between A1298C and the risk of meningioma and glioma (C vs. A: OR=1.08, 95%CI=1.00-1.17; AC vs. AA: OR=1.22, 95%CI=1.09-1.36; CC+AC vs. AA: 0R=1.18, 95%CI=1.06-1.30) (Figure [3](#F3){ref-type="fig"}). Then we implemented subgroup analysis by cancer type, and found no significant association of A1298C genotypes with meningioma susceptibility. In contrast, we detected a significantly increased risk of glioma (C vs. A: OR=1.13, 95%CI=1.01-1.27; AC vs. AA: OR=1.35, 95%CI=1.15-1.60; CC+AC vs. AA: OR=1.29, 95%CI=1.11-1.51). Further subgroup analysis showed significantly increased risk of meningioma and glioma in heterozygous model (AC vs. AA: OR=1.19, 95%CI=1.06-1.34), and dominant model (CC+AC vs. AA: OR=1.16, 95%CI=1.04-1.29). We also performed stratified analysis by ethnicity, and found a significant association of A1298C and the risk of meningioma and glioma in heterozygous model (AC vs. AA: OR=1.31, 95%CI=1.14-1.51) and dominant model (CC+AC vs. AA: OR=1.25, 95%CI=1.09-1.42) in Caucasian. However, there was no significant association with the risk of meningioma and glioma in Asian under any genetic model (Table [3](#T3){ref-type="table"}).

###### Meta-analysis of the association between A1298C polymorphism and brain tumor susceptibility in adults

  Comparison     Subgroup     Studies   Heterogeneity test   Association test   Model                 Publication bias               
  -------------- ------------ --------- -------------------- ------------------ --------------------- ------------------ --- ------- -------
  C vs. A        Overall      14        0.971                0                  1.08(1.00-1.17)       0.056              F   0.743   0.854
                 Meningioma   8         0.879                0                  1.04(0.93-1.15)       0.522              F           
                 Glioma       6         0.977                0                  **1.13(1.01-1.27)**   **0.033**          F           
                 Caucasian    11        0.978                0                  1.10(1.00-1.22)       0.059              F           
                 Asian        3         0.447                0                  1.05(0.93-1.18)       0.474              F           
                 PB           13        0.958                0                  1.07(0.99-1.17)       0.097              F           
                 HB           1         NA                   NA                 1.13(0.90-1.43)       0.296              F           
  AC vs. AA      Overall      14        0.717                0                  **1.22(1.09-1.36)**   **\<0.001**        F   0.584   0.189
                 Meningioma   8         0.649                0                  1.12(0.97-1.30)       0.119              F           
                 Glioma       6         0.868                0                  **1.35(1.15-1.60)**   **\<0.001**        F           
                 Caucasian    11        0.981                0                  **1.31(1.14-1.51)**   **\<0.001**        R           
                 Asian        3         0.13                 51                 1.11(0.86-1.44)       0.413              R           
                 PB           13        0.764                0                  **1.19(1.06-1.34)**   **0.002**          F           
                 HB           1         NA                   NA                 **1.50(1.05-2.14)**   **0.025**          F           
  CC vs. AA      Overall      14        0.941                0                  1.03(0.86-1.22)       0.771              F   0.274   0.131
                 Meningioma   8         0.636                0                  0.98(0.77-1.24)       0.854              F           
                 Glioma       6         0.987                0                  1.09(0.84-1.40)       0.531              F           
                 Caucasian    11        0.916                0                  0.99(0.79-1.25)       0.942              F           
                 Asian        3         0.51                 0                  1.07(0.82-1.40)       0.599              F           
                 PB           13        0.914                0                  1.01(0.84-1.22)       0.883              F           
                 HB           1         NA                   NA                 1.11(0.69-1.77)       0.676              F           
  CC+AC vs. AA   Overall      14        0.88                 0                  **1.18(1.06-1.30)**   **0.002**          F   0.743   0.328
                 Meningioma   8         0.836                0                  1.09(0.95-1.25)       0.208              F           
                 Glioma       6         0.921                0                  **1.29(1.11-1.51)**   **0.001**          F           
                 Caucasian    11        0.991                0                  **1.25(1.09-1.42)**   **0.001**          F           
                 Asian        3         0.212                35.5               1.08(0.92-1.27)       0.35               F           
                 PB           13        0.893                0                  **1.16(1.04-1.29)**   **0.009**          F           
                 HB           1         NA                   NA                 1.38(0.99-1.93)       0.058              F           
  CC vs. AA+AC   Overall      14        0.841                0                  0.93(0.78-1.09)       0.363              F   0.511   0.085
                 Meningioma   8         0.394                4.6                0.92(0.73-1.16)       0.483              F           
                 Glioma       6         0.983                0                  0.93(0.73-1.19)       0.561              F           
                 Caucasian    11        0.844                0                  0.87(0.70-1.09)       0.222              F           
                 Asian        3         0.416                0                  1.00(0.78-1.29)       0.990              F           
                 PB           13        0.786                0                  0.93(0.78-1.12)       0.448              F           
                 HB           1         NA                   NA                 0.89(0.58-1.36)       0.587              F           

OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not available; PB, population-based; HB, hospital-based

![Forest plot on the association between A1298C (rs1801311) and meningioma and glioma susceptibility in adults stratified by cancer type in the allele model](oncotarget-08-57265-g003){#F3}

Heterogeneity and sensitivity analysis {#s2_4}
--------------------------------------

Between-study heterogeneity was calculated by using Q statistics. Fixed-effect model was utilized if p-value of heterogeneity tests was more than 0.05 (P\>0.05) \[[@R17]\]; otherwise, the random-effect model was applied \[[@R18]\]. The sensitivity analysis was conducted by omitting each eligible study each time. The pooled ORs for the effects of A66G and A1298C on the risk of meningioma and glioma indicated that our results were statistically robust and stable (Figure [4](#F4){ref-type="fig"}).

![Sensitivity analyses of current meta-analysis in the allele model\
**(A)** A66G (rs1801394) and meningioma and glioma risk in adults. **(B)** A1298C (rs1801311) and meningioma and glioma risk in adults.](oncotarget-08-57265-g004){#F4}

Publication bias {#s2_5}
----------------

Both Begg's and Egger's tests were used to evaluate the publication bias of the studies \[[@R19], [@R20]\]. The results showed that there was no obvious publication bias in total population (Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}, Figure [5A, 5B](#F5){ref-type="fig"}).

![Begg's funnel plot for publication bias test of current meta-analysis in the allele model\
**(A)** A66G (rs1801394). **(B)** A1298C (rs1801311).](oncotarget-08-57265-g005){#F5}

DISCUSSION {#s3}
==========

Accumulating evidences indicate that the intake of folic acid has a negative correlation with cancer \[[@R21]--[@R23]\], including brain tumors \[[@R16]\]. It is known that folate metabolism will produce intermediate products that participate in nucleotide synthesis, DNA methylation and histone methylation \[[@R24]--[@R26]\]. Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) are key enzymes of folate metabolism that are involved in two important branches of folate metabolism: nucleotide synthesis and DNA methylation \[[@R24]\]. The polymorphisms of the genes encoding these enzymes will affect the process of folate metabolism and thus disturb DNA synthesis, repair and methylation, contributing to the occurrence of brain tumor \[[@R25]\].

Human MTHFR gene is located on 1p36.3 locus and contains 11 exons and 10 introns, encoding 656 amino acids \[[@R27], [@R28]\]. MTHFR protein turns 5,10-methylenetetrahydrofolate into 5-methylenetetrahydrofolate \[[@R29]\]. 5- methylenetetrahydrofolate is a collaborative substrate of homocysteine which is transformed to methionine, and provides methyl groups. MTHFR gene mutation could reduce methylene tetrahydrofolate reductase activity, leading to a higher plasma homocysteine concentration and abnormal metabolism of folic acid, and disturbed DNA synthesis and DNA damage repair \[[@R26], [@R30]--[@R33]\]. MTRR gene is located on the short arm of chromosome 5 (5p15.2-15.3) and contains 15 exons and 14 introns. The most common MTRR mutation is A66G polymorphism, causing the change of isoleucine to methionine, which can reduce enzyme activity and affect the metabolism of homocysteine \[[@R32]--[@R34]\].

Although increased number of case-control studies investigated the association of folate metabolism genetic variants with brain tumor susceptibility in adults, the results are inconclusive. Numerous studies have reported that folate metabolism genetic variants are associated with the risk of several cancers, including head and neck \[[@R35]\], lung \[[@R36]\], breast \[[@R8]\], and colorectal cancer \[[@R37], [@R38]\]. Semmler et al. reported the first case-control study showing that folate metabolism genetic variants was not significantly associated with brain tumor susceptibility \[[@R12]\]. However, Li et al. found that folate metabolism genetic variants may play a pivotal role in the pathogenesis of meningioma \[[@R15]\]. In addition, Bethke et al. reported that genetic variants in folate metabolism affected the risk of developing both meningioma and glioma \[[@R16]\]. To our knowledge, our study is the first comprehensive and systematical meta-analysis to evaluate potential association between two folate metabolism genetic variants (A1298C and A66G) and meningioma and glioma susceptibility in adults \[[@R12]--[@R16]\]. Our results showed that A1298C variant significantly increased meningioma and glioma susceptibility in Caucasian. Meanwhile, we observed that A66G variant was associated with increased meningioma and glioma susceptibility in Asian. Our results are consistent with a previous meta-analysis showing that MTRR rs1801394 polymorphism may increase the risk of meningioma \[[@R39]\].

The findings of current study should be interpreted with caution due to several potential limitations. First, the majority of the subjects included in present study were ethnically Caucasian, thus subjects from more diverse ethnicities should be included in future studies. Second, the number of subjects enrolled in certain subgroups was relatively small. Owing to the lack of the original data, we could not estimate meningioma and glioma susceptibility stratified by the gender, age, life-style and other risk factors. Data from large-scale multi-center studies are needed to verify the association between folate metabolism genetic variants (A1298C and A66G) and meningioma and glioma susceptibility in adults.

In conclusion, our findings suggest that folate metabolism genetic variants (A1298C and A66G) may increase the susceptibility of meningioma and glioma in adults. Further large-scale, multi-center and well-designed studies are necessary to investigate the potential function of genetic variation of folate metabolism in meningioma and glioma in adults.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We carried out a literature search in EMBASE, PubMed, and the Cochrane Library up to August 2016. We performed electronic searches using the terms "brain tumor" or "glioma" or "meningioma", "polymorphism\*" or "variant\*" or "mutation", "MTHFR" or "MTRR".

Selection criteria {#s4_2}
------------------

Two authors (GXL. and CCH.) independently screened titles and abstracts to identify relevant studies. Published case-control studies will be included in current meta-analysis if they reach the following criteria: (a) evaluating the association between folate metabolism genetic variants (A1298C and A66G) and brain tumor susceptibility in adults; (b) case-control studies on human, and published in English; (c) sufficient data for assessing the ORs and 95%CI, and P value. Exclusion criteria were: (a) case reports, letters, and review articles; (b) containing only case groups; (c) duplication of published articles.

Data extraction {#s4_3}
---------------

Two authors (GXL. and LXC) independently extracted data from all eligible studies. Data such as: (a) the first author name, publication date, country, ethnicity and source of control; (b) cancer types, frequency of cases and controls, involved genes and HWE status in controls. Any disagreements between the two authors were resolved through discussions and agreements

Statistical analyses {#s4_4}
--------------------

The strength of association between folate metabolism genetic variants (A1298C and A66G) and meningioma and glioma susceptibility in adults was calculated by odds ratios (ORs) with 95% confidence interval (CI). We used dominant, recessive, homozygote, heterozygote, allelic as the models. Stratified analyses were conducted by cancer type, ethnicity and sources of control. The pooled ORs were calculated for these five models. Heterogeneity was evaluated by using Q statistics (significant at p \< 0.05). A Fixed-effect model was utilized if p-value of heterogeneity tests were more than 0.05 (P\>0.05) \[[@R17]\]; otherwise, the random effect model was applied \[[@R18]\]. The sensitivity analysis was conducted by discarding each eligible study each time to estimate the stability of the results. Potential publication bias was evaluated by Egger's and Begg's tests (P \< 0.05 was considered significant) \[[@R19], [@R20]\]. All analyses were conducted by STATA 12.0 (Stata Corp LP, College Station, TX, USA).
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